{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972808",
  "id": "02972808",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250725",
  "time": "1527",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m4phgszg6n6f.pdf",
  "summary": "### **Material Information Summary**  \n**Document Type:** *Appendix 3G \u2013 Notification of Unquoted Securities Issuance*  \n\n- **Issuer:** Chimeric Therapeutics Limited (ASX: CHM)  \n- **Securities Issued:**  \n  - **141,250,000 unquoted options** (new class, code pending).  \n  - **Exercise Price:** AUD 0.004  \n  - **Expiry Date:** 31 March 2026.  \n  - **Underlying Security:** CHM ordinary shares.  \n- **Purpose:** Issued as part of termination of Placement Agreement with Lind Global Fund (approved at EGM on 23 July 2025).  \n- **Non-Cash Issuance:** No cash consideration received.  \n\n**Post-Issuance Capital Structure (Key Unquoted Securities):**  \n- **Performance Rights:** 7,227,904 (CHMAAB).  \n- **Existing Unquoted Options:** 286,587,331 (CHMAY).  \n- **New Unquoted Options:** 141,250,000 (pending code).  \n\n**Note:** No immediate trading impact (unquoted securities). Monitors for potential dilution upon option exercise.  \n\n---  \n**Brevity Note:** Excluded standard legal/administrative details (e.g., ISIN, director names). Focused on material capital structure changes.",
  "usage": {
    "prompt_tokens": 1877,
    "completion_tokens": 291,
    "total_tokens": 2168,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-25T05:49:46.436988"
}